Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Littner, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Littner, M. R.
(Chest. 2005;128:1128-1135.)
© 2005 American College of Chest Physicians

Effects of 24 Weeks of Lansoprazole Therapy on Asthma Symptoms, Exacerbations, Quality of Life, and Pulmonary Function in Adult Asthmatic Patients With Acid Reflux Symptoms*

Michael R. Littner, MD; Felix W. Leung, MD; E. David Ballard, II, MD; Bidan Huang, PhD; Nina K. Samra, MS; on behalf of the Lansoprazole Asthma Study Group{dagger}

* From the Department of Medicine (Drs. Littner and Leung), Veterans Affairs Greater Los Angeles Healthcare System, Sepulveda, CA; TAP Pharmaceutical Products Inc (Dr. Ballard and Ms. Samra), Lake Forest, IL; and Abbott Laboratories (Dr. Huang), Abbott Park, IL. {dagger} A list of Participating Investigators of the Lansoprazole Asthma Study Group is located in the Appendix.

Correspondence to: Michael Littner, MD, Veterans Affairs Medical Center (111P), Sepulveda, CA 91343; e-mail: mlittner{at}ucla.edu

Background: Difficult-to-control asthma has been associated with gastroesophageal acid reflux. Acid-suppressive treatment has been inconsistent in improving asthma control.

Objective: To determine whether a proton-pump inhibitor improves asthma control in adult asthmatic patients with acid reflux symptoms.

Design: Multicenter, double-blind, randomized, placebo-controlled trial.

Setting: Twenty-nine private practices and 3 academic practices in the United States.

Patients: Two hundred seven patients receiving usual asthma care including an inhaled corticosteroid (ICS). Patients had acid reflux symptoms and moderate-to-severe persistent asthma.

Intervention: Lansoprazole, 30 mg bid, or placebo, bid, for 24 weeks.

Measurements: The primary outcome measure was daily asthma symptoms by diary. Secondary asthma outcomes included rescue albuterol use, daily morning and evening peak expiratory flow, FEV1, FVC, asthma quality of life with standardized activities (AQLQS) questionnaire score, investigator-assessed symptoms, exacerbations, and oral corticosteroid-treated exacerbations.

Results: Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo. The AQLQS emotional function domain improved at 24 weeks (p = 0.025) with lansoprazole therapy. Fewer patients receiving lansoprazole (8.1% vs 20.4%, respectively; p = 0.017) had exacerbations and oral corticosteroid-treated (ie, moderate-to-severe) exacerbations (4% vs 13.9%, respectively; p = 0.016) of asthma. A post hoc subgroup analysis revealed that fewer patients receiving one or more long-term asthma-control medications in addition to an ICS experienced exacerbations (6.5% vs 24.6%, respectively; p = 0.016) and moderate-to-severe exacerbations (2.2% vs 17.5%, respectively; p = 0.021) with lansoprazole therapy.

Conclusion: In adult patients with moderate-to-severe persistent asthma and symptoms of acid reflux, treatment with 30 mg of lansoprazole bid for 24 weeks did not improve asthma symptoms or pulmonary function, or reduce albuterol use. However, this dose significantly reduced asthma exacerbations and improved asthma quality of life, particularly in those patients receiving more than one asthma-control medication.

Key Words: asthma • exacerbation • gastroesophageal acid reflux • lansoprazole • proton-pump inhibitor




This article has been cited by other articles:


Home page
 ChestHome page
R. R. Kempainen, K. Savik, T. P. Whelan, J. M. Dunitz, C. S. Herrington, and J. L. Billings
High Prevalence of Proximal and Distal Gastroesophageal Reflux Disease in Advanced COPD
Chest, June 1, 2007; 131(6): 1666 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J M FitzGerald and P G Gibson
Asthma exacerbations {middle dot} 4: Prevention.
Thorax, November 1, 2006; 61(11): 992 - 999.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. S. Menon, M. Al-Hajji, A. Morice, M. R. Littner, F. W. Leung, B. Huang, E. D. Ballard II, and N. K. Samra
Gastroesophageal Reflux Disease and Asthma: The Role of Proton Pump Inhibitors
Chest, June 1, 2006; 129(6): 1732 - 1733.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. O. Kiljander, S. M. Harding, S. K. Field, M. R. Stein, H. S. Nelson, J. Ekelund, M. Illueca, O. Beckman, and M. B. Sostek
Effects of Esomeprazole 40 mg Twice Daily on Asthma: A Randomized Placebo-controlled Trial
Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1091 - 1097.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.